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In the natural history of type 2 diabetes (T2DM), individuals progress from normal glucose
tolerance (NGT) to impaired glucose tolerance (IGT) to overt T2DM and this progression has
been demonstrated in populations of diverse ethnic background. It is widely recognised
that both insulin resistance and beta-cell dysfunction are important in the pathogenesis of
glucose intolerance. In populations with a high prevalence of T2DM, insulin resistance is
well established long before the development of any impairment in glucose homeostasis,
particularly in subjects with ectopic fat accumulation. However, as long as the beta cell
is able to secrete sufficient amounts of insulin to offset the severity of insulin resistance,
glucose tolerance remains normal. This dynamic interaction between insulin secretion and
insulin resistance is essential to the maintenance of NGT and interruption of this cross-
talk between the beta cell and peripheral tissues results in the progressive deterioration
of glucose homeostasis. In this paper the role of beta-cell function is reviewed, as well as
the role of ectopic fat accumulation and insulin resistance in the development of type 2
diabetes.
© 2011 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
In the natural history of type 2 diabetes (T2DM), individ-
uals progress from normal glucose tolerance (NGT) to im-
paired glucose tolerance (IGT) to overt T2DM and this pro-
gression has been demonstrated in populations of diverse
ethnic background [1]. Both insulin secretion and insulin re-
sistance are important elements in the pathogenesis of type
2 diabetes. Subjects with insulin resistance require more in-
sulin to promote glucose uptake by peripheral tissues, and
genetically predisposed individuals may lack the necessary
beta-cell secretory capacity. The resulting insulin deficiency
disrupts the regulation of glucose production in the liver,
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glucose uptake in muscle, and the release of fatty acid from
adipose tissue. The outcome is postprandial, and later fast-
ing hyperglycemia [2].
Ectopic fat accumulation (in particular visceral fat but
also liver and pancreas fat) is associated to increased insulin
resistance and glucose production thus increasing the risk of
developing type 2 diabetes.
2. Main determinants of fasting and
postprandial hyperglycemia
Fasting hyperglycemia is strictly correlated to reduced periph-
eral glucose clearance and increased endogenous glucose
production (EGP). In diabetic subjects, despite higher fast-
ing insulin secretion rates and insulin concentrations, glu-
cose clearance is decreased as effect of insulin resistance
[3]. Fasting glucose concentration is also proportional to
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increased EGP, in particular to increased gluconeogenesis
(Fig. 1), (i.e., glucose synthesized from non-glucose substrate
such as lactate, pyruvate, aminoacids and glycerol) rather
than glycogenolysis [4]. Increased gluconeogenesis is present
not only in diabetic patients but also in obese non-diabetic
subjects. However, in the latter hyperglycemia does not de-
velop because of compensatory decrease in glycogenolysis
[5] (Fig. 2). It is only when hepatic autoregulation is lost (and
glycogenolysis is not suppressed) that EGP, and consequently
glucose concentration, is increased [5]. Gluconeogenesis is
a process that occurs mainly in the liver, but also the kid-
ney contributes to glucose production via gluconeogenesis.
Although net renal glucose production is almost negligible
in subjects with normal fasting glucose it can become an
important contribution to hyperglycemia in diabetic patients
[6]. Subjects with abdominal fat accumulation are highly
insulin resistant, especially at the level of the liver [7,8].
Visceral fat accumulation is associated with increased glu-
coneogenesis (Fig. 2) but not with increased glycogenolysis
[4,7]. This is because visceral fat is highly lipolytic and FFA
and glycerol are released directly into the portal vein and
thus into the liver where they are used to produce glucose
or re-esterified into triglycerides and released as lipoprotein
(Fig. 1).
Postprandial hyperglycemia is due mainly to insulin resis-
tance and impaired beta-cell function. Following glucose
ingestion, the plasma glucose concentration rises, insulin
secretion is stimulated, and the combination of hyper-
glycemia plus hyperinsulinemia (i) enhances tissue glucose
disposal (primarily muscle); (ii) suppresses endogenous (pri-
marily hepatic) glucose production (EGP); and (iii) augments
Fig. 1 – Increased adipose tissue and visceral fat leads to ectopic fat accumulation in liver, muscle and pancreas and to
insulin resistance with the consequence of increased hepatic glucose production, decreased muscle glucose uptake, and
impaired suppression of lipolysis with the consequence of fatty acids overload to target tissues.
splanchnic (liver plus gut) glucose uptake. We have shown
that T2DM subjects with mild hyperglycemia have rates of
glucose production and glucose absorption after a mixed
meal similar to control subjects, but their glucose clearance
was markedly reduced [9]. The beta-cell function in response
to the meal is impaired and the glucose sensitivity (i.e., the
slope of the dose response of the insulin secretion vs glu-
cose concentration) is significantly decreased [9]. In diabetic
subjects with overt fasting hyperglycemia, EGP is increased
already during fasting and thus during meal absorption it is
not appropriately suppressed despite high insulin levels. The
dynamic interaction between insulin secretion and insulin
resistance is essential to the maintenance of normal glucose
tolerance and the interruption of this cross-talk between
the beta-cell peripheral tissues and the liver results in the
progressive deterioration of glucose homeostasis [3] (Fig. 1).
3. Role of insulin secretion/beta-cell function
in the development of T2DM
The beta cell produces and secretes insulin to maintain
circulating glucose concentrations within a narrow, physi-
ological range. Insulin is secreted from pancreatic beta cells
throughout the day at a basal rate and in response to a
change in glucose concentration (e.g. after a meal). The
insulin secreting beta cells represent the majority of islet
endocrine cells (60–80%) in a normal pancreas, followed by
glucagon containing cells (alpha cells, 20–30%), somatostatin
(delta) cells (5–15%), and pancreatic polypeptide (PP) cells.
Beta-cell dysfunction plays an important role in the tran-
S62 D I A B E T E S R E S E A R C H A N D C L I N I C A L P R A C T I C E 9 3 S ( 2 0 1 1 ) S 6 0 – S 6 5
Fig. 2 – Relationship between increased gluconeogenesis, fasting plasma glucose concentrations and visceral fat
accumulation. Adapted from Gastaldelli et al. [4,8].
sition from normal glucose tolerance to hyperglycemia [1,10].
In the fasting state, insulin secretion rate increases with the
level of insulin resistance (Fig. 3): in lean NGT subjects mean
values are around 60 pmol/min m2 but we can find values
more than twice higher in obese subjects [11]. As glucose
tolerance deteriorates and type 2 diabetes develops, basal
insulin secretion increases as well. T2DM develops when the
beta-cell secretory capacity is not sufficient to overcome the
insulin resistance of the tissues.
In subjects with T2DM, several studies have reported
decreased both beta-cell mass and insulin secretory gran-
ules [12]. The relative contribution of reduced beta-cell mass
and beta-cell dysfunction to hyperglycemia is still debated
[13,14]. However, beta-cell mass reduction is not the only de-
fect responsible for hyperglycemia. Even in the case of a 50%
reduction, i.e., after experimental partial pancreatectomy,
normoglycemia can be maintained by relatively small pan-
creas remnants. Therefore, alterations of insulin secretion
Fig. 3 – Mean insulin secretion rates after OGTT in lean (left panel) and obese subjects (right panel), divided according to
glucose tolerance and fasting glycemia (G1 = FPG < 140m g/dl; G2 = FPG from 140 to 180 mg/dl; G3 = FPG > 180 mg/dl).
White bar represents fasting ISR, while dark bar represents incremental secretion after OGTT. Adapted from Ferrannini et
al. [40] and Ferrannini and Mari [10].
(either intrinsic or acquired) have to play a role. In fact, func-
tional defects such as abnormal pulsatility of basal insulin
secretion and loss of first-phase insulin release in response
to a glucose challenge were demonstrated to be important
contributors to the development of type 2 diabetes [15].
In response to a change in glucose concentration (e.g. af-
ter meal ingestion), insulin is released in two phases. The
first phase, a short, small burst, prevents and decreases
glucose concentration [10]. Later, a more sustained second-
phase insulin is released proportionally to the plasma glu-
cose elevation. After a meal the intestine secretes incretin
hormones (e.g. glucagon-like peptide-1, GLP-1 and GIP) that
potentiate insulin secretion. It has been shown that GLP-1
secretion is blunted in diabetic or obese patients and con-
tribute to impaired beta-cell function and that the treatment
with GLP-1 analogs can normalize hyperglycemia by stim-
ulating insulin secretion in diabetic patients and delaying
gastric emptying [16].
D I A B E T E S R E S E A R C H A N D C L I N I C A L P R A C T I C E 9 3 S ( 2 0 1 1 ) S 6 0 – S 6 5 S63
4. Role of insulin resistance and defects in
insulin action in the development of T2DM
Abnormalities in insulin action are present in most patients
before type 2 diabetes is diagnosed. Although genetically in-
fluenced, insulin resistance is closely associated with obesity
and ectopic fat accumulation, and may be mediated by in-
creased FFAs. Insulin resistance may be best described as the
loss of insulin regulation by the normal amount of insulin,
which is a condition of reduced insulin sensitivity. Insulin
stimulates glucose uptake mainly in skeletal muscle and
adipocytes [17] but also in the liver [18].
Insulin resistance in the muscle determines a reduced mus-
cle uptake of glucose, mainly because of defects in intracel-
lular insulin signaling. However, since certain lipid species
are second messengers themselves, it is possible that in-
creased tissue lipid availability, as seen in insulin resistant
states, may activate pathways that lead to attenuation of
insulin signals [19]. It has been observed that insulin re-
sistance in skeletal muscle during FFA infusion rises when
triglycerides start to accumulate inside muscle fibers [20] in
excess of their oxidation. One of the major defects is in the
impairment in insulin receptor substrate (IRS)-1-associated
phosphatidyl inositol (PI)-3-kinase activity. In fact, excessive
storage of intramyocellular lipids may be associated with
accumulation of intracellular signaling molecules (i.e., ce-
ramide, diacylglycerol, and protein kinase C, with activation
of the Iκβ-kinase (IKK-β)/Iκβ-nuclear factor (NF)-κβ pathway)
[21] that may feed back to inhibit PI-3-kinase activity associ-
ated with IRS-1.
Insulin resistance at the level of adipose tissue is also im-
portant. Besides promoting glucose uptake into adipocytes,
insulin has two other important roles: promoting fatty acid
re-esterification into triglyceride, and inhibiting triglyceride
hydrolysis and release of FFA into the circulation (i.e. lipol-
ysis). Impairment of insulin action at the level of adipose
tissue results in excess release of free fatty acids (FFA) into
the circulation. Several studies have shown that elevated
FFA concentrations are linked with the onset of peripheral
and hepatic insulin resistance [22,23] (Fig. 1). Elevated FFA
and intracellular lipids appear to inhibit insulin signaling,
leading to a reduction in insulin-stimulated muscle glucose
transport that may be mediated by a decrease in GLUT-
4 translocation [22]. The resulting suppression of muscle
glucose transport leads to reduced muscle glycogen synthe-
sis and glycolysis. In the liver, elevated FFA may contribute
to hyperglycemia by antagonizing the effects of insulin on
endogenous glucose production. It has been shown that in
healthy humans, acute and chronic lipid infusion determines
peripheral and hepatic IR [22,24], induces hyperinsulinemia
by increasing both fasting and glucose-stimulated insulin
secretion [24,25].
Insulin resistance in the liver. Insulin acts at the level of
the liver through a direct and/or indirect effect (i.e. on glu-
cose transport and/or intracellular enzymes). During fasting,
insulin acts in the liver mainly by reducing glycogenolysis
[22,26], while during postprandial state the effect is on both
GNG and glycogenolysis [9]. Insulin resistant subjects have
increased fasting GNG compared to their lean counterpart
[27], despite normal EGP. On the other hand, during the eu-
glycemic hyperinsulinemic clamp the normal suppression of
EGP is blunted in IR subjects, and the residual EGP is mainly
due to unrestrained GNG [26]. This can be considered as
an early manifestation of hepatic insulin resistance (Fig. 1).
Hepatic insulin resistance has been found to exist in both
obese non-diabetic and obese type 2 diabetic patients and
is considered to be a dominant component in the patho-
genesis of fasting hyperglycemia in type 2 diabetes [28]. It
has been suggested that hepatic insulin resistance may be
directly related to visceral adiposity, independent of total fat
mass [7,29]. Hepatic insulin resistance is also a characteristic
feature of subjects with non-alcoholic fatty liver [7,30].
Although the mechanisms of insulin resistance in the
liver are not perfectly understood, a role for elevated plasma
FFA has been postulated (Fig. 1). While raised FFA concen-
trations promote liver GNG [31], when plasma FFA were ex-
perimentally lowered in healthy volunteers, changes in GNG
mirrored the changes in plasma FFA, while glycogenolysis
was inversely correlated with FFA concentrations [31]. An-
other possible mechanism is through the activity of phos-
phoenolpyruvate carboxykinase (PEPCK), which is thought
to be the rate-limiting enzyme responsible for converting
several gluconeogenic precursors in the gluconeogenic path-
ways. It has been shown that both a high-fat diet and high-
sucrose diet increase GNG through an increase in PEPCK
flux.
5. Role of increased circulating FFA and ectopic
fat accumulation in the development of T2DM
Ectopic fat accumulation, in particular in the abdomen, has
been associated with a reduction in peripheral and hepatic
insulin sensitivity [8]. It has been theorized that reduced glu-
cose uptake in adipocytes accelerates lipolysis and raises the
levels of FFAs, which worsen both peripheral and hepatic in-
sulin resistance [32]. However, despite the strong association,
visceral fat does not seem to have a direct role in the devel-
opment of peripheral insulin resistance. In fact, although
highly lipolytic, visceral fat does not represent more than
10–15% of total fat. On the other hand visceral fat is an im-
portant source of inflammatory cytokine such as TNF-alpha,
TGF-beta, and IL6 that can directly affect insulin-mediated
glucose uptake. The case of intramuscular fat deposition dif-
fers. Excess circulating FFA are associated with increased
accumulation of intra- and inter-myocellular triglycerides in
muscular cells and this has been associated with lipotoxicity
and impaired glucose metabolism in the muscle [33].
FFA derived from visceral fat lipolysis are released into
the portal vein and drained by the liver (Fig. 1). This not
only promotes hepatic fat accumulation but can also cause
hepatic insulin resistance [7,34]. Nielsen et al. have shown
a direct relationship between visceral fat size and FFA re-
lease to the liver [35] and we and others have found a direct
relationship between visceral and hepatic fat accumulation
[7]. Intra-hepatic triglyceride accumulation has been associ-
ated with increased hepatic insulin resistance, i.e. excessive
glucose production during fasting and an impaired suppres-
sion of EGP at high insulin concentrations, e.g. during a
euglycemic hyperinsulinemic clamp [7].
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Excess FFA also influences insulin secretion and beta-cell
function. FFA have per se a direct effect on insulin secretion
and insulin resistance [36]. Increased plasma FFA levels after
2–4 h and 24 h of lipid infusion have been shown to enhance
both basal and glucose-stimulated insulin secretion [12,25].
In healthy humans, acute and chronic lipid infusion deter-
mines peripheral and hepatic IR, induces hyperinsulinemia
by increasing both fasting and glucose-stimulated insulin se-
cretion [25,37]. On the other hand, an overnight reduction of
plasma FFA results in an improvement in beta-cell function
with better glucose tolerance, despite reduction in circulat-
ing insulin levels.
Chronic exposure to hyperglycemia and high circulating
FFA can contribute to both functional and survival pancreatic
defects [15]. In fact, FFA can be taken up by the pancreas and
accumulate as intracellular triglycerides and cause lipotoxic-
ity [38] (Fig. 1). It has been shown that intrapancreatic fat is
negatively associated with parameters of beta-cell function
state, such as insulinogenic index, early glucose-stimulated
insulin secretion, beta-cell glucose sensitivity, and rate sensi-
tivity (adjusted for insulin resistance state) [39]. However, the
relationship holds only in non-diabetic subjects suggesting
that once diabetes occurs, factors additional to pancreatic fat
account for further beta-cell function decline. Thus, excess
release of FFA into the circulation, as occurring in obesity
or abdominal fat accumulation, has the double effect to pro-
mote insulin secretion and insulin resistance.
6. Summary
In summary, in populations with a high prevalence of T2DM,
insulin resistance is well established long before the devel-
opment of any impairment in glucose homeostasis but as
long as the beta cell is able to secrete sufficient amounts
of insulin to offset the severity of insulin resistance, glu-
cose tolerance remains normal. The first defect in insulin
secretion is the progressive loss of the first phase insulin
release in response to food intake, allowing postprandial hy-
perglycemia to develop. The glucose sensitivity of the beta
cell is also progressively deteriorated. Thus, early in the de-
velopment of T2DM, fasting glucose concentrations are often
within normal ranges while postprandial hyperglycemia is
already present. Presence of ectopic fat, in particular vis-
ceral fat, excess FFA release and lack of inhibition of lipolysis
(insulin resistance of the adipose tissue) worsen this state.
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